Tharimmune Advances TH104 as National Security Solution Against Weaponized Fentanyl, Secures $5.47M Funding
Key Insights
Tharimmune secured approximately $5.47 million in equity financing during Q2/Q3 2025 to advance its lead asset TH104, a buccal film formulation of nalmefene designed to protect military personnel and first responders from weaponized fentanyl exposure.
The FDA confirmed that no additional clinical trials are required for TH104's 505(b)(2) NDA submission for temporary prophylaxis against high-potency opioid contamination, utilizing an expedited "in silico" pathway.
TH023, the company's oral monoclonal antibody targeting TNF-alpha (search), demonstrated successful oral delivery of infliximab in preclinical studies using the proprietary Soteria® platform, with plans for first-in-human trials within 12 months.
Tharimmune Inc. (Nasdaq: THAR) has secured approximately $5.47 million in equity financing while advancing its lead asset TH104 as a critical medical countermeasure against weaponized fentanyl threats. The clinical-stage biotechnology company announced significant progress across its pipeline, including positive FDA feedback for TH104's regulatory pathway and promising preclinical results for its oral antibody program TH023.
TH104 Addresses Critical National Security Threat
The company's lead asset, TH104, represents a buccal film formulation of nalmefene specifically designed to protect military personnel and chemical incident responders from high-potency opioid contamination. The U.S. government has increasingly recognized fentanyl and related compounds as significant national security threats due to their extreme potency and potential for mass casualty incidents if weaponized.
TH104 offers substantial advantages over existing solutions like naloxone auto-injectors. While naloxone has a half-life of approximately 60-90 minutes to 2 hours, nalmefene provides a significantly longer plasma half-life of approximately 8 to 11 hours. This extended duration of action means TH104 provides sustained protection, potentially reducing the need for continuous monitoring and multiple redosing in high-risk environments.
The buccal film formulation allows for rapid and convenient administration, a critical benefit for personnel wearing full protective gear where intramuscular injections can be impractical or delayed.
FDA Confirms Expedited Regulatory Pathway
In a pivotal development, the FDA confirmed that no additional clinical trials appear necessary prior to a 505(b)(2) NDA submission for TH104's proposed indication: "Temporary Prophylaxis of Respiratory and/or Nervous System Depression in Military Personnel and Chemical Incident Responders Entering an Area Contaminated with High-Potency Opioids."
This expedited pathway allows Tharimmune to leverage existing extensive safety and efficacy data for nalmefene, combined with the company's human pharmacokinetic data, enabling an "in silico" (computer simulation) submission model that significantly accelerates potential availability.
Positive Phase 1 clinical data for TH104, presented at Digestive Disease Week (DDW) and the European Association for the Study of the Liver (EASL) International Liver Congress in May 2025, demonstrated that buccal administration achieves systemic exposure to nalmefene with reliable and predictable absorption and delayed phase 1 metabolism.
Breakthrough in Oral Antibody Delivery
Tharimmune is developing TH023, a novel oral monoclonal antibody targeting Tumor Necrosis Factor-alpha (search) (TNF-alpha (search)), licensed through Intract Pharma (search) (UK). The program addresses a longstanding challenge in biopharmaceutical development: overcoming the formidable physiological barriers of the gastrointestinal tract for large molecule delivery.
Preclinical studies in a murine model successfully demonstrated oral delivery of infliximab using the proprietary protease enzyme stabilized platform (Soteria®), achieving serum concentrations significantly higher than standard therapeutic levels. The studies confirmed enzymatic protection and successful in vivo delivery to both local colonic tissue and systemic circulation.
This proprietary formulation showed superior tissue penetration compared to traditional permeation enhancers, highlighting its potential for treating both local gastrointestinal diseases like Inflammatory Bowel Disease (search) and systemic inflammatory conditions.
Commercial Potential and Development Timeline
With the global infliximab market valued in the multibillions, an oral formulation represents substantial commercial opportunity. Traditional TNF-alpha (search) inhibitors like infliximab (Remicade®) require intravenous infusions or subcutaneous injections, which can be burdensome for patients. TH023 aims to provide a convenient oral pill form that could dramatically improve patient compliance and quality of life while reducing healthcare system burdens.
Building on promising preclinical results, Tharimmune plans to optimize TH023's formulation and dosing regimen and prepare for a first-in-human clinical trial within the next 12 months.
Strategic Leadership Enhancements
Tharimmune has strategically enhanced its leadership structure to support pipeline advancement. James Gordon Liddy (CDR US Navy SEAL (Ret.)), a renowned counter-terrorism and critical infrastructure expert, has been appointed to the Board of Directors and serves as Key Strategic Advisor. His expertise in national security and preparedness, including roles in designing policy for the Global War on Terrorism and architecting the Navy's Anti-Terrorism Force Protection Plan, provides invaluable guidance for TH104's development and deployment.
Additional key appointments include Sireesh Appajosyula as Chief Executive Officer, Vincent LoPriore as Executive Chairman of the Board, Clay Kahler bringing life sciences manufacturing expertise, and Gary Stetz contributing financial and corporate governance experience.
"Over the past year, Tharimmune has achieved considerable milestones, particularly in advancing our lead candidate TH104 to a potential NDA with clear direction from FDA on a pathway while demonstrating preclinical success with our oral antibody program, TH023," stated CEO Sireesh Appajosyula. "Our strategic focus on high-impact solutions, from protecting military and first responders to redefining treatment paradigms for chronic inflammatory diseases (search), reflects our unwavering commitment to patient well-being and shareholder value."